Tyra Biosciences, Inc. (TYRA) Bundle
An Overview of Tyra Biosciences, Inc. (TYRA)
General Summary of Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (NASDAQ: TYRA) is a biotechnology company focused on developing targeted therapies for cancer patients with genetically defined diseases. Founded in 2018, the company has leveraged its proprietary SNÅP platform to discover and develop drug candidates that address significant unmet medical needs. Tyra's primary product candidates include TYRA-300, TYRA-200, and TYRA-430, which are designed to target specific genetic alterations in tumors.
As of 2024, Tyra Biosciences has made substantial advances in its clinical programs, with ongoing trials aimed at treating various forms of cancer, including advanced hepatocellular carcinoma and other solid tumors. The company reported total sales of $0, as it has yet to generate revenue from product sales, focusing instead on research and development to bring its candidates to market.
Company's Financial Performance in the Latest Financial Reports
In the financial reports for the nine months ended September 30, 2024, Tyra Biosciences reported a net loss of $60.9 million, compared to a net loss of $46.3 million for the same period in 2023. The increase in losses is attributed to higher operating expenses, particularly in research and development, which totaled $57.9 million, an increase from $41.8 million in 2023. General and administrative expenses also rose to $16.5 million from $12.5 million.
Tyra's cash flows for the nine months ended September 30, 2024, showed net cash used in operating activities of $50.2 million, compared to $36.6 million in 2023. The net cash used in investing activities was $105.4 million, primarily due to purchases of marketable securities. However, financing activities provided $201.4 million, mainly from a private placement of common stock and pre-funded warrants completed in February 2024, yielding gross proceeds of approximately $200 million.
| Financial Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Loss | $60.9 million | $46.3 million |
| Research & Development Expenses | $57.9 million | $41.8 million |
| General & Administrative Expenses | $16.5 million | $12.5 million |
| Net Cash Used in Operating Activities | $50.2 million | $36.6 million |
| Net Cash Used in Investing Activities | $105.4 million | $0.2 million |
| Net Cash Provided by Financing Activities | $201.4 million | $1.2 million |
Introduction to Company as One of the Leading Companies in the Industry
Tyra Biosciences has positioned itself as a leader in the biotechnology industry, focusing on precision medicine and targeted therapies. With a robust pipeline of innovative drug candidates, the company is dedicated to addressing the needs of patients with specific genetic mutations that drive cancer progression. The successful completion of its 2024 Private Placement has fortified its financial position, enabling continued investment in research and development. Tyra's commitment to advancing its clinical programs and the potential of its proprietary technologies contribute to its recognition as a promising player in the competitive landscape of oncology therapeutics.
Mission Statement of Tyra Biosciences, Inc. (TYRA)
Mission Statement Overview
Tyra Biosciences, Inc. (TYRA) has articulated its mission statement to reflect its commitment to developing transformative therapies for patients with cancer and other serious diseases. This mission acts as a guiding star for the company, aligning its strategic initiatives and operational activities toward long-term objectives. The mission emphasizes the importance of innovation, collaboration, and quality in delivering impactful healthcare solutions.
Core Components of the Mission Statement
Innovation
Innovation is at the heart of Tyra's mission, driving the development of cutting-edge therapies. The company leverages its proprietary SNÅP platform to discover and develop targeted therapies that address significant unmet medical needs in oncology. For example, Tyra is advancing its lead product candidates, including TYRA-300 and TYRA-200, which are designed to target specific genetic mutations in cancer patients. The R&D expenses for the nine months ended September 30, 2024, reached $57.9 million, marking an increase from $41.8 million in the same period of 2023, underscoring Tyra's commitment to innovation.
Collaboration
Collaboration is essential for Tyra's success, as it engages with various stakeholders including research organizations, healthcare professionals, and regulatory bodies. The company has entered into numerous partnerships to enhance its research capabilities and expedite clinical trials. For instance, Tyra's collaborations with contract research organizations (CROs) have been vital in supporting its clinical development programs. In 2024, Tyra completed a private placement that raised approximately $200 million, providing necessary funding to foster collaborative efforts in clinical research.
Quality
Quality assurance is a foundational element of Tyra's mission, ensuring that all therapies developed meet the highest standards of efficacy and safety. The company adheres to rigorous regulatory guidelines throughout its drug development process. As of September 30, 2024, Tyra reported an accumulated deficit of $225.7 million, which reflects its ongoing investment in quality-driven research and development. Additionally, the increase in general and administrative expenses to $16.5 million from $12.5 million in the previous year highlights the company's focus on maintaining quality in its operations.
| Financial Metric | 2024 (Nine Months Ended Sept 30) | 2023 (Nine Months Ended Sept 30) | Change |
|---|---|---|---|
| Research and Development Expenses | $57.9 million | $41.8 million | $16.1 million Increase |
| General and Administrative Expenses | $16.5 million | $12.5 million | $4.0 million Increase |
| Net Loss | $(60.9 million) | $(46.3 million) | $(14.6 million) Increase |
| Cash, Cash Equivalents, and Marketable Securities | $360.1 million | N/A | N/A |
Vision Statement of Tyra Biosciences, Inc. (TYRA)
Vision of Tyra Biosciences, Inc.
As of 2024, Tyra Biosciences, Inc. (TYRA) envisions a future where innovative therapies transform the treatment of diseases driven by genetic mutations. The company aims to leverage its proprietary SNÅP platform to develop targeted therapies that address significant unmet medical needs. This vision reflects a commitment to enhancing patient outcomes through precision medicine.
Commitment to Innovation
Tyra's vision emphasizes a strong commitment to innovation in drug development. The company is focused on advancing its pipeline, which includes:
- TYRA-300: A candidate targeting skeletal dysplasias.
- TYRA-200: An investigational FGFR1/2/3 inhibitor for various advanced solid tumors.
- TYRA-430: A novel FGFR4/3 biased inhibitor aimed at hepatocellular carcinoma (HCC).
As of September 30, 2024, Tyra has incurred research and development expenses totaling $57.9 million for the nine months ended, reflecting a $16.1 million increase from the previous year, driven by costs associated with ongoing clinical trials.
Focus on Patient-Centric Solutions
Tyra Biosciences positions itself as a patient-centric organization, striving to develop therapies that significantly improve the quality of life for patients. The company aims to create solutions that are not only effective but also well-tolerated, minimizing adverse effects. As part of this commitment, Tyra is actively engaged in clinical studies, including:
- SURF201: Evaluating the safety and efficacy of TYRA-200.
- SURF431: A Phase 1 study for TYRA-430 in advanced HCC, which received FDA approval to proceed.
Strategic Collaborations and Partnerships
To realize its vision, Tyra is focused on strategic collaborations that enhance its research capabilities and market reach. The company completed a private placement in February 2024, raising approximately $200 million, which will be utilized to fund ongoing research efforts and expand its development programs.
| Funding Activity | Amount (in millions) | Date |
|---|---|---|
| Private Placement | $200 | February 2024 |
| IPO Proceeds | $181.2 | September 2021 |
| Total R&D Expenses (9M 2024) | $57.9 | N/A |
Long-Term Vision for Growth
Tyra envisions sustainable growth through its innovative product pipeline and commitment to addressing serious medical conditions. The company anticipates that its cash, cash equivalents, and marketable securities amounting to $360.1 million as of September 30, 2024, will support its operations through at least 2026.
In pursuing its vision, Tyra aims to achieve regulatory approvals for its product candidates, which will enable the company to transition to a revenue-generating entity. The focus on developing biomarker-driven therapies underscores its commitment to precision medicine and the potential to meet significant market needs.
Core Values of Tyra Biosciences, Inc. (TYRA)
Innovation
The core value of innovation at Tyra Biosciences, Inc. is fundamental to its mission as a biotechnology company. This value emphasizes the importance of developing cutting-edge therapies to address unmet medical needs, particularly in the field of oncology and genetic disorders.
In 2024, Tyra Biosciences has demonstrated its commitment to innovation through the advancement of its product pipeline. The company has invested approximately $57.9 million in research and development (R&D) for the nine months ended September 30, 2024, a significant increase from $41.8 million during the same period in 2023. This investment supports ongoing clinical trials for its key product candidates, including TYRA-300, TYRA-200, and TYRA-430, which are designed to target specific genetic alterations in cancer patients.
| Product Candidate | Clinical Phase | Indication | R&D Expense (2024) |
|---|---|---|---|
| TYRA-300 | Phase 1 | Achondroplasia | $5,720,000 |
| TYRA-200 | Phase 1 | FGFR2+ Cholangiocarcinoma | $3,501,000 |
| TYRA-430 | Phase 1 | Hepatocellular Carcinoma | $3,513,000 |
Integrity
Integrity is a cornerstone of Tyra Biosciences' operations, guiding its interactions with stakeholders, including patients, employees, and investors. This value is reflected in the company's commitment to transparent communication and ethical practices.
In 2024, Tyra has upheld its integrity through robust governance practices. The company reported a net loss of $60.9 million for the nine months ended September 30, 2024, compared to a net loss of $46.3 million for the same period in 2023. Despite these losses, Tyra remains focused on maintaining transparency with shareholders regarding its financial health and future prospects. The company also has established an Employee Stock Purchase Plan (ESPP), which allows employees to purchase shares at a discount, fostering a culture of ownership and trust.
Collaboration
Collaboration is essential for Tyra Biosciences as it seeks to leverage partnerships to enhance its research capabilities and expedite the development of its therapies. This value is evident in Tyra's strategic alliances with contract research organizations (CROs) and academic institutions.
In 2024, the company has engaged in multiple collaborations, which have allowed it to expand its research initiatives. Tyra's R&D expenses include significant investments in external research partnerships, which accounted for a total of $57.9 million for the nine months ending September 30, 2024. These partnerships are critical as they enable Tyra to access specialized expertise and resources, thereby accelerating the development and commercialization of its innovative therapies.
Accountability
Accountability at Tyra Biosciences means taking responsibility for the outcomes of its actions, particularly in relation to patient safety and product efficacy. This value ensures that the company adheres to regulatory standards and maintains high-quality practices in its clinical trials.
In 2024, Tyra has been accountable for its financial performance, reporting a comprehensive loss of $22.1 million for the three months ended September 30, 2024. The company has also committed to rigorous clinical trial protocols, ensuring that its studies are conducted ethically and transparently. This commitment is underscored by the successful initiation of clinical trials for TYRA-300 and TYRA-430, which are designed to provide critical data on the safety and effectiveness of these therapies.
Excellence
Excellence is at the heart of Tyra Biosciences’ mission to deliver high-quality therapeutic solutions. This value drives the company to meet and exceed industry standards in research and product development.
In 2024, Tyra has made strides towards excellence by enhancing its R&D capabilities. The company reported total operating expenses of $74.4 million for the nine months ended September 30, 2024, highlighting its commitment to investing in the quality of its research and development efforts. Furthermore, Tyra's focus on excellence is reflected in its strategic decision to expand its pipeline with innovative candidates like TYRA-300, TYRA-200, and TYRA-430, which aim to address significant medical needs in targeted patient populations.
Tyra Biosciences, Inc. (TYRA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Tyra Biosciences, Inc. (TYRA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Tyra Biosciences, Inc. (TYRA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Tyra Biosciences, Inc. (TYRA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.